Association Between the XRCC1 Arg399Gln Polymorphism and Head and Neck Cancer Susceptibility: A Meta-Analysis Based on Case-Control Studies

Published data regarding the association between the XRCC1 Arg399Gln polymorphism and head and neck cancer (HNC) susceptibility showed inconsistent results. This meta-analysis of eligible literatures was performed to draw a more precise estimation of the relationship. We systematically searched PubMed, Embase, and Web of Science with a time limit of Oct 28, 2013. Summary odds ratios (ORs) with 95% CIs were used to assess the strength of association between XRCC1 Arg399Gln polymorphism and HNC susceptibility using random-effect model. A total of 27 case-control studies including 5942 cases and 9041 controls were included for analysis. Meta-analysis of total studies showed that the XRCC1 Arg399Gln variant carriers were not susceptible to HNC (AA vs. GG: OR = 0.92, 95% CI = 0.77-1.11; AG vs. GG: OR = 1.05, 95% CI = 0.76-1.44; the dominant model AA + AG vs. GG: OR = 1.00, 95% CI = 0.78-1.29; the recessive model AA vs. AG + GG: OR = 0.91, 95% CI = 0.71-1.16). Further, subgroup analyses by ethnicity and source of controls did not identify any significant associations of XRCC1 Arg399Gln polymorphism with head and neck susceptibility in any populations. Our meta-analysis suggested that the XRCC1 Arg399Gln polymorphism was not a risk factor for HNC susceptibility.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000337166900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Biochemistry & Molecular BiologyCell BiologyGenetics & HereditySCI(E)1ARTICLEningwang1978@163.com; yajiewa0459@163.com6378-3873